arrow
B

Burkhard Möller

University of Bern
H指数:41
被引数:5,612

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Difficult-to-Manage Psoriatic Arthritis: Prevalence, Phenotype, and Clinical Burden in Real-World Practice: insights from the SCQM registry

难治性银屑病关节炎:真实世界实践中的患病率、表型及临床负担:SCQM登记研究的见解

2026-10-210
OAAI
Progression of sacroiliac joint structural lesions in axial spondyloarthritis: a longitudinal comparative study of MRI and radiography among European patients in routine clinical care

轴性脊柱关节炎患者骶髂关节结构病变的进展:欧洲常规临床护理中患者的MRI与放射影像纵向比较研究

2026-10-130
OAAI
Early diagnosis of axial spondyloarthritis is associated with less long-term spinal structural damage: a longitudinal analysis of the Swiss Clinical Quality Management in rheumatic diseases registry

轴脊柱关节炎的早期诊断与长期脊柱结构损伤较少相关:瑞士风湿病临床质量管理登记数据库的纵向分析

2026-09-240
OAAI
Site-specific articular response to TNF inhibitor in axial spondyloarthritis: a European cohort study

轴向脊柱关节炎中肿瘤坏死因子抑制剂对特定关节位点的反应:一项欧洲队列研究

2026-07-240
OAAI
Disparities in the organisation of national healthcare systems for treatment of patients with psoriatic arthritis and axial spondyloarthritis across Europe

欧洲各国在组织治疗银屑病关节炎和轴向脊柱关节炎患者方面的国家医疗体系存在差异。

2025-06-010
OAAI
Handling of missing component information for common composite score outcomes used in axial spondyloarthritis research when complete-case analysis is unbiased
2025-02-280
OAAI
Effect of Online Training on the Reliability of Assessing Sacroiliac Joint Radiographs in Axial Spondyloarthritis: A Randomized, Controlled Study
2024-09-151
PRE
Comparing DAPSA, DAPSA28, and DAS28-CRP in Patients With Psoriatic Arthritis Initiating a First Tumor Necrosis Factor Inhibitor Across Nine European Countries
2024-08-190
OAAI
Drug effectiveness of 2nd and 3rd TNF inhibitors in psoriatic arthritis - relationship with the reason for withdrawal from the previous treatment
2024-07-011
OAAI
Sex Differences in the Effectiveness of First-Line Tumor Necrosis Factor Inhibitors in Psoriatic Arthritis: Results From the European Spondyloarthritis Research Collaboration Network
2024-02-253
OAAI
Patient-Reported Outcomes (PROs) and PRO Remission Rates in 12,262 Biologic-Naive Patients With Psoriatic Arthritis Treated With Tumor Necrosis Factor Inhibitors in Routine Care

在常规护理中使用肿瘤坏死因子抑制剂治疗的12,262生物未接受过治疗的银屑病关节炎患者的患者报告结局 (PROs) 和缓解率

2024-01-150
OA
Differences and similarities between the EULAR/ASAS-EULAR and national recommendations for treatment of patients with psoriatic arthritis and axial spondyloarthritis across Europe
2023-10-016
OA
Management of Peripheral Arthritis in Patients With Psoriatic Arthritis: An Updated Literature Review Informing the 2021 GRAPPA Treatment Recommendations (Vol 50, pg 119, 2023)
2022-12-010
OA